Cognition Therapeutics targets mid-2027 start for DLB psychosis Phase 3

Cognition Therapeutics reported second-quarter 2026 financial results and a business update on August 6, 2026. CEO Lisa Ricciardi said discussions with the FDA brought clarity on key aspects of the company's planned Phase 3 trial for people with dementia with Lewy bodies who experience psychosis, known as DLB psychosis.¹ She added that the company is focused on starting the Phase 3 study in mid-2027 using an improved tablet formulation.¹

On the regulatory front, the company said it held a planned meeting with the FDA to discuss the design of a registrational study in DLB psychosis, and will provide a timing update once endpoints are aligned.¹ Separately, Cognition disclosed it received a Notice of Allowance covering a patent application for a polymorphic crystalline form of zervimesine, addressing composition of matter, the production process, and a therapeutic method for treating Alzheimer's disease and DLB. Once issued, the patent would extend protection through 2045, before any patent-term extension.¹

The company also said it extended its expanded access program for zervimesine in DLB, with the extension running through 2027 and supported by a new philanthropic donor, according to the release's business highlights section. In addition, Cognition presented a poster at the Alzheimer's Association International Convention outlining a proposed Phase 3 study design for zervimesine in DLB psychosis.¹

On financials, cash, cash equivalents, and restricted cash equivalents as of June 30, 2026 were approximately $34.8 million, with $21.6 million remaining in obligated grant funds from the National Institute of Aging.¹ The company said its cash is projected to support operations and capital spending into the fourth quarter of 2027. Net loss for the quarter was $3.9 million, or $(0.04) per basic and diluted share, compared with a net loss of $6.7 million, or $(0.11) per share, in the same period of 2025.¹